Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.

Michael B. Gatch; Michael J Forster

doi:10.1007/s00213-016-4237-6

Δ(9)-Tetrahydrocannabinol-like effects of novel synthetic cannabinoids in mice and rats.

Michael B. Gatch, Michael J Forster

Psychopharmacology May 2016 DOI: 10.1007/s00213-016-4237-6 (opens in new tab)

Read Full Text

Relevant Not relevant

Study at a glance

AI-extracted from the abstract

Characteristics	Preclinical in vitro and in vivo pharmacology study Peer reviewed
Population	Mice (locomotor activity) and rats trained to discriminate Δ9-THC
Interventions	ADBICA ADB-PINACA THJ-2201 RCS-4 JWH-122 JWH-210 CP 55940 3 4-Methylenedioxy-methamphetamine (MDMA)
Topics	Cannabis
Keywords	Abuse liability Cannabinoids Drug discrimination Locomotor activity Mouse Rat
Key points	All six synthetic cannabinoids bound CB1 receptors with nanomolar affinity and acted as full agonists, depressed mouse locomotor activity for 1.5 to nearly 4 hours, and fully substituted for Δ9-THC's discriminative stimulus effects in rats. The authors conclude these compounds produce behavioral effects common to abused cannabinoids, suggesting substantial abuse liability.

Abstract

Novel cannabinoid compounds continue to be marketed as "legal" marijuana substitutes, even though little is known about their molecular and behavioral effects. Six of these compounds (ADBICA, ADB-PINACA, THJ-2201, RCS-4, JWH-122, JWH-210) were tested for in vitro and in vivo cannabinoid-like effects to determine their abuse liability. Binding to and functional activity at CB1 cannabinoid receptors was tested. Locomotor activity in mice was tested to screen for behavioral activity and to identify behaviorally active dose ranges and times of peak effect. Discriminative stimulus effects of the six compounds were tested in rats trained to discriminate Δ(9)-tetrahydrocannabinol (Δ(9)-THC). ADBICA, ADB-PINACA, THJ-2201, RCS-4, JWH-122, and JWH-210 showed high affinity binding at the CB1 receptor at nanomolar affinities (0.59 to 22.5 nM), and all acted as full agonists with nanomolar potencies (0.024 to 111 nM) when compared to the CB1 receptor full agonist CP 55940. All compounds depressed locomotor activity below 50 % of vehicle responding, with depressant effects lasting 1.5 to nearly 4 h. All compounds fully substituted (<80 % Δ(9)-THC-appropriate responding) for the discriminative stimulus effects of Δ(9)-THC. 3,4-Methylenedioxy-methamphetamine (MDMA) was tested as a negative control and did not substitute for Δ(9)-THC (11 % Δ(9)-THC-appropriate responding). All six of the compounds acted at the CB1 receptor and produced behavioral effects common to abused cannabinoid compounds, which suggest that these compounds have substantial abuse liability common to controlled synthetic cannabinoid compounds.

Comparable studies

Other preclinical and animal studies on cannabis, most cited first.

Study	Year	Design
Cognitive Impairment Induced by Delta9-tetrahydrocannabinol Occurs through Heteromers between Cannabinoid CB1 and Serotonin 5-HT2A Receptors Mice	2015	Preclinical study
Interaction of drugs of abuse and maintenance treatments with human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2). hMDR1- and hBCRP-transfected HEK293 cells and hMDR1- and hBCRP-MDCKII cells	2010	In vitro study
Long-term hippocampal interneuronopathy drives sex-dimorphic spatial memory impairment induced by prenatal THC exposure Mice prenatally exposed to THC, including conditional CB1R knockout mice	2020	Animal experimental study
Chronic cannabis promotes pro-hallucinogenic signaling of 5-HT2A receptors through Akt/mTOR pathway Mice exposed to chronic THC early in life	2018	Animal experimental study
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain Spontaneously hypertensive rats (SHRs) and Wistar rats	2014	Animal experimental study

Citations in the library

Cited by 4

Cites 8

and 3 more in the library